Biodegradable PLA-PEG-PPG-PEG Nanoparticles for Peptide Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current delivery systems for therapeutic peptides, such as those used in cancer therapy, face challenges like enzymatic degradation, immunogenicity, and short lifespan in the blood, leading to inefficiencies in reaching tumor tissues and high costs due to the need for large and frequent doses.
Innovation Solution
Development of biodegradable polymeric nanoparticles formed from a block copolymer of poly(lactic acid) chemically modified with hydrophilic-hydrophobic block copolymers, specifically PLA-PEG-PPG-PEG, which are non-toxic, tunable in size, and capable of encapsulating therapeutic agents for targeted delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If therapeutic peptides are administered directly, then they show high specificity and ease of synthesis, but they suffer from enzymatic degradation, immunogenicity, and short lifespan in the blood
Solution Approach 1:
The patent uses biodegradable polymeric nanoparticles as an intermediary carrier to deliver therapeutic peptides. The nanoparticles protect the peptides from enzymatic degradation and immunogenicity while extending their circulation lifespan, allowing the peptides to reach target tissues effectively without direct administration
Solution Approach 2:
The patent employs a block copolymer matrix forming a flexible nanoparticle shell that encapsulates the therapeutic peptide. This flexible polymeric structure provides protection against degradation while allowing controlled release and targeting to tumor tissues
2Quantity of substance
If large amounts of therapeutic peptide are administered frequently, then adequate intracellular concentration is achieved, but cost and inconvenience of therapy increase
Solution Approach 1:
The patent creates sustained-release polymeric nanoparticles that continuously deliver therapeutic peptides to target tissues over extended periods. This continuous delivery maintains adequate intracellular concentrations without requiring frequent large-dose administrations, reducing both cost and inconvenience
Solution Approach 2:
The patent modifies the delivery system by changing from direct peptide administration to nanoparticle-encapsulated delivery. This parameter change enables controlled release kinetics, extending the effective duration of action and reducing the frequency and amount of dosing required
3Reliability
If conventional chemotherapeutic agents are used, then they can treat cancer, but they lack specificity and cause dose-limiting toxicities
Solution Approach 1:
The patent confers local quality to the therapeutic peptide by enabling selective accumulation in tumor tissues through the enhanced permeability and retention (EPR) effect and active targeting mechanisms. This localized delivery concentrates the drug at the tumor site while minimizing exposure to healthy tissues, reducing toxicity without compromising efficacy
Solution Approach 2:
The patent introduces polymeric nanoparticles as an intermediary delivery vehicle that carries the therapeutic peptide selectively to tumor tissues. This intermediary system enables targeted delivery, improving the therapeutic index by concentrating drug action at the disease site while sparing healthy tissues from toxic effects
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These nanoparticles enhance the intracellular concentration of drugs in cancer cells, reduce toxicity, and prolong the drug's half-life in vivo, enabling effective and sustained release of therapeutic agents while minimizing dosage requirements.
Implementation Method 1
biodegradable polymeric nanoparticles formed from a block copolymer of poly(lactic acid) chemically modified with hydrophilic-hydrophobic block copolymers, specifically PLA-PEG-PPG-PEG
Data Source
AI summary
The present invention relates to the field of nanotechnology, in particular, to the production of biodegradable polymeric nanoparticles. The present invention provides a biodegradable polymeric nanoparticle made up of a block copolymer and a process for producing the same. The nanoparticles are produced without the use of any emulsifiers and have a size ranging from 30-120 nm. The methods of controlling the drug loading capacity are disclosed along with the process of producing entity-loaded nanoparticles. Compositions comprising the nanoparticles and their use in therapeutics, diagnostics and theranostics are also disclosed.